Bernhard R. M. Ehmer
Chairman chez BIOTEST AG
Fortune : 107 356 $ au 29/02/2024
Profil
Bernhard R.
M.
Ehmer is a German businessperson who has been at the helm of 7 different companies and currently occupies the position of Chairman-Supervisory Board for Biotest AG.
He is also on the board of Affimed NV, Affimed GmbH and Achilles Therapeutics Plc.
Dr. Ehmer previously was Chief Executive Officer & Managing Director at BioPheresis Technologies, Inc. and Chief Executive Officer & Managing Director at Biopheresis GmbH (a subsidiary of BioPheresis Technologies, Inc.), Head-Clinical Research & Development Operations at Merck KGaA, VP, Head-Strategic Planning & Alliance Management at Merck KGaA, Managing Director & Senior Vice President at ImClone Systems International GmbH, Chairman for Symphogen A, Chairman-Management Board at Biotest AG, President & Chief Executive Officer of Neovii Biotech GmbH, President for ImClone Systems Corp.
and Head-Therapeutics & Medical Operations at Boehringer Mannheim GmbH.
Bernhard R.
M.
Ehmer received an undergraduate degree from Ludwig-Maximilians-Universität München and an undergraduate degree from Ruprecht-Karls-Universität Heidelberg.
Détentions connues dans des sociétés publiques
Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
---|---|---|---|---|
AFFIMED N.V.
0,12% | 15/03/2023 | 178 333 ( 0,12% ) | 107 356 $ | 29/02/2024 |
Postes actifs de Bernhard R. M. Ehmer
Sociétés | Poste | Début |
---|---|---|
AFFIMED N.V. | Director/Board Member | 21/01/2016 |
ACHILLES THERAPEUTICS PLC | Director/Board Member | 04/05/2022 |
BIOTEST AG | Chairman | 05/05/2022 |
Affimed GmbH
Affimed GmbH Miscellaneous Commercial ServicesCommercial Services Part of Affimed NV, Affimed GmbH is a clinical leader in innate immuno-oncology. The private company, based in Heidelberg, Germany, develops proprietary cancer-targeting bispecific antibodies that activate the innate immune system to kill tumor cells. Affimed leads clinical development of innate cell engagers for solid/hematologic tumors as monotherapy, in combination with NK cells or with checkpoint inhibitors. Adolf Hoess has been the CEO of the German company since 2010. | Director/Board Member | 01/01/2016 |
Anciens postes connus de Bernhard R. M. Ehmer
Sociétés | Poste | Fin |
---|---|---|
Symphogen A/S
Symphogen A/S Pharmaceuticals: MajorHealth Technology Symphogen A/S provides antibody therapeutics for the treatment of cancers. It offers oncology products and creates selected antibody mixtures that address multiple oncology targets in a single drug product. The firm’s pipeline is fueled by its technology suite capable of identifying, selecting, manufacturing, and characterizing optimal antibody mixtures. The company was founded by Kirsten Aarup Drejer, Thomas Feldthus, Eigil Bjerl Nielsen, Anker Gunvald Lundemose, Kim Arthur Hueg, and John Soerensen Haurum in 2000 and is headquartered in Ballerup, Denmark. | Chairman | 01/06/2020 |
BIOTEST AG | Chief Executive Officer | 01/04/2019 |
ADMA BIOLOGICS, INC. | Director/Board Member | 15/02/2018 |
ImClone Systems International GmbH
ImClone Systems International GmbH BiotechnologyHealth Technology ImClone Systems International GmbH develops novel therapeutic products. The company is based in Heidelberg, Germany. | Corporate Officer/Principal | 01/01/2012 |
Neovii Biotech GmbH
Neovii Biotech GmbH BiotechnologyHealth Technology Neovii Biotech GmbH develops and markets biopharmaceutical products in the field of transplantation. The company was founded in 2003 and is headquartered in Gräfelfing, Germany. | Chief Executive Officer | 01/05/2008 |
Formation de Bernhard R. M. Ehmer
Ruprecht-Karls-Universität Heidelberg | Undergraduate Degree |
Ludwig-Maximilians-Universität München | Undergraduate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 6 |
---|---|
MERCK KGAA | Health Technology |
ADMA BIOLOGICS, INC. | Health Technology |
AFFIMED N.V. | Health Technology |
BIOTEST AG | Health Technology |
ATON | Health Technology |
ACHILLES THERAPEUTICS PLC | Health Technology |
Entreprise privées | 8 |
---|---|
Symphogen A/S
Symphogen A/S Pharmaceuticals: MajorHealth Technology Symphogen A/S provides antibody therapeutics for the treatment of cancers. It offers oncology products and creates selected antibody mixtures that address multiple oncology targets in a single drug product. The firm’s pipeline is fueled by its technology suite capable of identifying, selecting, manufacturing, and characterizing optimal antibody mixtures. The company was founded by Kirsten Aarup Drejer, Thomas Feldthus, Eigil Bjerl Nielsen, Anker Gunvald Lundemose, Kim Arthur Hueg, and John Soerensen Haurum in 2000 and is headquartered in Ballerup, Denmark. | Health Technology |
Biopheresis GmbH
Biopheresis GmbH Miscellaneous Commercial ServicesCommercial Services Part of BioPheresis Technologies, Inc., Biopheresis GmbH is a German company that provides cancer treatments. The private company is based in Heidelberg, Germany. | Commercial Services |
BioPheresis Technologies, Inc.
BioPheresis Technologies, Inc. Medical SpecialtiesHealth Technology BioPheresis Technologies, Inc. develops technology and medical devices for the treatment of cancer. The company was founded by M. Rigdon Lentz in 1995 and is headquartered in Atlanta, GA. | Health Technology |
Boehringer Mannheim GmbH | |
ImClone Systems International GmbH
ImClone Systems International GmbH BiotechnologyHealth Technology ImClone Systems International GmbH develops novel therapeutic products. The company is based in Heidelberg, Germany. | Health Technology |
ImClone Systems Corp. | Health Technology |
Affimed GmbH
Affimed GmbH Miscellaneous Commercial ServicesCommercial Services Part of Affimed NV, Affimed GmbH is a clinical leader in innate immuno-oncology. The private company, based in Heidelberg, Germany, develops proprietary cancer-targeting bispecific antibodies that activate the innate immune system to kill tumor cells. Affimed leads clinical development of innate cell engagers for solid/hematologic tumors as monotherapy, in combination with NK cells or with checkpoint inhibitors. Adolf Hoess has been the CEO of the German company since 2010. | Commercial Services |
Neovii Biotech GmbH
Neovii Biotech GmbH BiotechnologyHealth Technology Neovii Biotech GmbH develops and markets biopharmaceutical products in the field of transplantation. The company was founded in 2003 and is headquartered in Gräfelfing, Germany. | Health Technology |